Go to the list of all blogs
Allana's Avatar
published in Blogs
Dec 07, 2018
Healthcare Spending at $3.5 Trillion, But Still Down from Previous Years

Healthcare Spending at $3.5 Trillion, But Still Down from Previous Years

A new study by the Centers for Medicare and Medicaid Services says Americans paid $3.5 trillion on healthcare in 2017, which amounts to $10,739 per person. Despite a growth rate of 3.9%, spending was actually down from a growth rate of 4.8% in 2016 and 5.8% in 2015. According to the report: "In 2017, health care spending growth returned to these lower rates and the health spending share of GDP stabilized for the first time since 2013."

Private health insurance had the highest spending with an increase of 4.2 percent to $1.2 trillion, in 2017. The lowest spending was on retail prescription drugs, which reached $333.4 billion in 2017, an increase of only 0.4 percent.

 

Related Ticker: IYH

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


IYH in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 08, 2026

IYH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 45 cases where IYH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +0.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where IYH advanced for three days, in 255 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IYH as a result. In 70 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for IYH turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 40 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

IYH moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IYH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for IYH entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks to track the investment results of the Russell 1000 Health Care RIC 22.5/45 Capped Index composed of U.S. equities in the healthcare sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index. The underlying index measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares U.S. Healthcare ETF (IYH) ETF is 75.82B. The market cap for tickers in the group ranges from 3.61B to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is OGN at 3.61B.

High and low price notable news

The average weekly price growth across all stocks in the iShares U.S. Healthcare ETF (IYH) ETF was 17%. For the same ETF, the average monthly price growth was 65%, and the average quarterly price growth was 350%. UTHR experienced the highest price growth at 12%, while CAI experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the iShares U.S. Healthcare ETF (IYH) ETF was 6%. For the same stocks of the ETF, the average monthly volume growth was 44% and the average quarterly volume growth was 10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 48
Price Growth Rating: 48
SMR Rating: 65
Profit Risk Rating: 77
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
IYH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.
Healthcare Spending at $3.5 Trillion, But Still Down from Previous Years